Next Article in Journal
Hafnia alvei Pneumonia: From Bees to Human Beings
Previous Article in Journal
Periodontal Disease in Seropositive Rheumatoid Arthritis: Scoping Review of the Epidemiological Evidence
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Perspectives on Passive Antibody Therapy and Peptide-Based Vaccines Against Emerging Pathogens Like SARS-CoV-2

Independent Researcher, Calle San Jose, Torrevieja 03181, Spain
GERMS 2021, 11(2), 287-305; https://doi.org/10.18683/germs.2021.1264
Submission received: 16 January 2021 / Revised: 25 April 2021 / Accepted: 1 June 2021 / Published: 2 June 2021

Abstract

The current epidemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is raising awareness of the need to act faster when dealing with new pathogens. Exposure to an emerging pathogen generates an antibody response that can be used for preventing and treating the infection. These antibodies might have a high specificity to a target, few side effects, and are useful in the absence of an effective vaccine for treating immunocompromised individuals. The approved antibodies against the receptor-binding domain (RBD) of the viral spike protein of SARS-CoV-2 (e.g., regdanvimab, bamlanivimab, etesevimab, and casirivimab/imdevimab) have been selected from the antibody repertoire of B cells from convalescent patients using flow cytometry, next-generation sequencing, and phage display. This encourages use of these techniques especially phage display, because it does not require expensive types of equipment and can be performed on the lab bench, thereby making it suitable for labs with limited resources. Also, the antibodies in blood samples from convalescent patients can be used to screen pre-made peptide libraries to identify epitopes for vaccine development. Different types of vaccines against SARS-CoV-2 have been developed, including inactivated virus vaccines, mRNA-based vaccines, non-replicating vector vaccines, and protein subunits. mRNA vaccines have numerous advantages over existing vaccines, such as efficacy, ease of manufacture, safety, and cost-effectiveness. Additionally, epitope vaccination may constitute an attractive strategy to induce high levels of antibodies against a pathogen and phages might be used as immunogenic carriers of such peptides. This is a point worth considering further, as phage-based vaccines have been shown to be safe in clinical trials and phages are easy to produce and tolerate high temperatures. In conclusion, identification of the antibody repertoire of recovering patients, and the epitopes they recognize, should be an attractive alternative option for developing therapeutic and prophylactic antibodies and vaccines against emerging pathogens.
Keywords: Emerging Pathogen; SARS-CoV-2; Passive Antibody Therapy; Peptide Vaccine; Phage Display; Therapeutic Antibody Emerging Pathogen; SARS-CoV-2; Passive Antibody Therapy; Peptide Vaccine; Phage Display; Therapeutic Antibody

Share and Cite

MDPI and ACS Style

Palma, M. Perspectives on Passive Antibody Therapy and Peptide-Based Vaccines Against Emerging Pathogens Like SARS-CoV-2. GERMS 2021, 11, 287-305. https://doi.org/10.18683/germs.2021.1264

AMA Style

Palma M. Perspectives on Passive Antibody Therapy and Peptide-Based Vaccines Against Emerging Pathogens Like SARS-CoV-2. GERMS. 2021; 11(2):287-305. https://doi.org/10.18683/germs.2021.1264

Chicago/Turabian Style

Palma, Marco. 2021. "Perspectives on Passive Antibody Therapy and Peptide-Based Vaccines Against Emerging Pathogens Like SARS-CoV-2" GERMS 11, no. 2: 287-305. https://doi.org/10.18683/germs.2021.1264

APA Style

Palma, M. (2021). Perspectives on Passive Antibody Therapy and Peptide-Based Vaccines Against Emerging Pathogens Like SARS-CoV-2. GERMS, 11(2), 287-305. https://doi.org/10.18683/germs.2021.1264

Article Metrics

Back to TopTop